期刊文献+

HER2分子与肿瘤靶向治疗 被引量:17

HER2 and Tumor Targeting Therapy
暂未订购
导出
摘要 HER2分子是表皮生长因子受体家族的第二位成员,对细胞的生长、分化及存活有着重要的调节作用,在乳腺癌、卵巢癌、肺腺癌、肾细胞癌中其过表达与否是患者预后的重要指标。研究表明它与表皮生长因子受体家族其他3位成员形成异二聚体,通过多种信号转导途径促进肿瘤的增殖、转移、耐药性的产生,是肿瘤基因治疗的重要靶位点。 HER2 molecule is the second member of the epidermal growth factor receptor family and plays an important role in the growth, differentiation, and survival of cells. Its excessive expression has been an important indicator of the prognosis of breast cancer, ovarian cancer, adenocarcinoma of lung, and renal cell carcinoma. Studies suggest that HER2 overexpression on the surface of cell membrane, by forming heterodimer with the other members, promotes the proliferation and metastasis of tumors and increases the resistance of tumors to chemical therapy. HER2 receptor is a potential target for gene therapy. On the basis of further understanding of molecular mechanisms of its tumorigenesis and development, two strategies, HER2-directing and HER2-targeting, are now being used in the HER2-related studies.
出处 《医学分子生物学杂志》 CAS CSCD 2006年第2期129-132,共4页 Journal of Medical Molecular Biology
基金 国家高技术研究发展计划(863计划)(No.2004AA217071) 国家重点基础研究发展计划(973计划)(No.2004CB518805)~~
关键词 HER2分子 表皮生长因子受体 基因治疗 HER2 EGFR gene therapy
  • 相关文献

参考文献23

  • 1[1]TISEO M,LOPREVITE M,ARDIZZONI A,et al.Epidermal growth factor receptor inhibitors:a new prospective in the treatment of lung cancer[J].Curr Med Chem Anti-Canc Agents,2004,4(2):139-148.
  • 2[2]IIVANAINEN E,NELIMARKKA L,ELENIUS V,et al.Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor[J].FASEB J,2003,17(12):1609-1621.
  • 3[3]WINGENS M,WALMA T,VAN INGEN H,et al.Structural analysis of an epidermal growth factor/transforming growth factoralpha chimera with unique ErbB binding specificity[J].J Biol Chem,2003,278(40):39114-39123.
  • 4[4]SHIN H S,LEE H J,NISHIDA M,et al.Betacellulin and amphiregulin induce upregulation of cyclin D1 and DNA synthesis activity through differential signaling pathways in vascular smooth muscle cells[J].Circ Res,2003,93(4):302-310.
  • 5[5]WANG S C,LIEN H C,XIA W,et al.Hung MC binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2[J].Cancer Cell,2004,6(3):251-261.
  • 6[6]GALIEGUE S,CASELLAS P,KRAMAR A,et al.Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival[J].Clin Cancer Res,2004,10(6):2058-2064.
  • 7[7]KLEER C G,VAN GOLEN K L,BRAUN T,et al.Persistent Ecadherin expression in inflammatory breast cancer[J].Mod Pathol,2001,14(5):458-464.
  • 8[8]KUNITOMO K,INOUE S,ICHIHARA F,et al.A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel[J].Hum Pathol,2004,35(3):379-381.
  • 9[9]Kakonen S M,Mundy G R.Mechanisms of osteolytic bone metastases in breast carcinoma[J].Cancer,2003,97 (3 Suppl):834-839.
  • 10[10]CHEN S Y,YANG A G,CHEN J D,et al.Potent antitumour activity of a new class of tumour-specific killer cells[J].Nature,1997,385(6611):78-80.

同被引文献154

引证文献17

二级引证文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部